Tremfya

Tremfya

guselkumab

Manufacturer:

Johnson & Johnson
Concise Prescribing Info
Contents
Guselkumab
Indications/Uses
Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy.
Dosage/Direction for Use
SC 100 mg at wk 0 & 4, then every 8 wk thereafter.
Special Precautions
Discontinue treatment if serious hypersensitivity reaction occurs & institute appropriate therapy. May increase risk of infection. Not to be initiated in patients w/ any clinically important active infection until the infection resolves or is adequately treated. Evaluate patients for TB infection prior to initiating treatment. Monitored for signs & symptoms of active TB during & after treatment. Consider completion of all age appropriate immunizations. Avoid use of live vaccines. Avoid during pregnancy. Breast-feeding.
Adverse Reactions
Resp tract infections. Increased transaminases; headache; diarrhea; arthralgia; inj site reactions.
Drug Interactions
Not to be given concurrently w/ live vaccines.
MIMS Class
Immunosuppressants / Psoriasis, Seborrhea & Ichthyosis Preparations
ATC Classification
L04AC16 - guselkumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Tremfya soln for inj 100 mg/mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in